Is SLS or PRAX more profitable?

Praxis Precision Medicines' return on equity of -34.15% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Praxis Precision Medicines N/A -34.15% -32.42%

Does the media refer more to SLS or KRYS?

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.30 beat SELLAS Life Sciences Group's score of 0.46 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SLS or NUVL?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.21 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is SLS or NUVL more profitable?

SELLAS Life Sciences Group's return on equity of -35.91% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Nuvalent N/A -40.11% -35.43%

Does the media refer more to SLS or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 9 mentions for Kymera Therapeutics and 8 mentions for SELLAS Life Sciences Group. Kymera Therapeutics' average media sentiment score of 1.24 beat SELLAS Life Sciences Group's score of 0.46 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SELLAS Life Sciences Group (SLS) Competitors

$15.46 +2.06 (+15.37%)

As of 08/21/2026 04:00 PM Eastern

Compare

SLS vs. PRAX, PTGX, KRYS, NUVL, and KYMR

Should you buy SELLAS Life Sciences Group stock or one of its competitors? SELLAS Life Sciences Group's main competitors and comparable companies include Praxis Precision Medicines (PRAX), Protagonist Therapeutics (PTGX), Krystal Biotech (KRYS), Nuvalent (NUVL), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SELLAS Life Sciences Group compare to Praxis Precision Medicines?

SELLAS Life Sciences Group (NASDAQ:SLS) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 35.32%. Praxis Precision Medicines has a consensus target price of $585.95, suggesting a potential upside of 55.90%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

Praxis Precision Medicines' return on equity of -34.15% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.62 beat SELLAS Life Sciences Group's score of 0.46 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Praxis Precision Medicines. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Praxis Precision Medicines	$8.55M	1,227.30	-$303.27M	-$12.93	N/A

SELLAS Life Sciences Group has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market.

Summary

Praxis Precision Medicines beats SELLAS Life Sciences Group on 12 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Protagonist Therapeutics has a net margin of 29.40% compared to SELLAS Life Sciences Group's net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Protagonist Therapeutics	29.40%	12.03%	11.23%

In the previous week, Protagonist Therapeutics had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 8 mentions for SELLAS Life Sciences Group. Protagonist Therapeutics' average media sentiment score of 1.02 beat SELLAS Life Sciences Group's score of 0.46 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 35.32%. Protagonist Therapeutics has a consensus target price of $140.53, indicating a potential downside of 8.93%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protagonist Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

SELLAS Life Sciences Group has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Protagonist Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics beats SELLAS Life Sciences Group on 14 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Krystal Biotech?

SELLAS Life Sciences Group (NASDAQ:SLS) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Krystal Biotech has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential downside of 35.32%. Krystal Biotech has a consensus price target of $365.40, indicating a potential upside of 5.43%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SELLAS Life Sciences Group has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.30 beat SELLAS Life Sciences Group's score of 0.46 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 54.82% compared to SELLAS Life Sciences Group's net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Krystal Biotech	54.82%	19.34%	17.65%

Summary

Krystal Biotech beats SELLAS Life Sciences Group on 14 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Nuvalent?

SELLAS Life Sciences Group (NASDAQ:SLS) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 35.32%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Nuvalent's higher possible upside, analysts clearly believe Nuvalent is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 8 more articles in the media than Nuvalent. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 0 mentions for Nuvalent. SELLAS Life Sciences Group's average media sentiment score of 0.46 beat Nuvalent's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Overall Sentiment
SELLAS Life Sciences Group	Neutral
Nuvalent	Neutral

SELLAS Life Sciences Group's return on equity of -35.91% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Nuvalent	N/A	-40.11%	-35.43%

Summary

SELLAS Life Sciences Group beats Nuvalent on 8 of the 13 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Kymera Therapeutics had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 9 mentions for Kymera Therapeutics and 8 mentions for SELLAS Life Sciences Group. Kymera Therapeutics' average media sentiment score of 1.24 beat SELLAS Life Sciences Group's score of 0.46 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

SELLAS Life Sciences Group has higher earnings, but lower revenue than Kymera Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Kymera Therapeutics	$39.21M	254.05	-$311.35M	-$3.24	N/A

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential downside of 35.32%. Kymera Therapeutics has a consensus price target of $125.65, suggesting a potential upside of 4.88%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

Summary

Kymera Therapeutics beats SELLAS Life Sciences Group on 10 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.12B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-73.62	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	22.74	16.80	13.05	6.20
Net Income	-$26.86M	-$12.50M	$3.47B	$348.59M
7 Day Performance	20.97%	3.29%	2.09%	0.08%
1 Month Performance	25.28%	8.23%	6.64%	3.88%
1 Year Performance	709.42%	55.05%	25.02%	16.98%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	0.7974 of 5 stars	$15.46 +15.4%	$10.00 -35.3%	+709.4%	$3.12B	N/A	N/A	10	News Coverage Options Volume Gap Up High Trading Volume
PRAX Praxis Precision Medicines	3.0492 of 5 stars	$376.38 +2.6%	$579.55 +54.0%	+670.5%	$10.24B	$8.55M	N/A	110	Analyst Forecast
PTGX Protagonist Therapeutics	2.0106 of 5 stars	$158.62 +2.3%	$140.53 -11.4%	+168.5%	$10.04B	$281.99M	154.00	120	Positive News Analyst Upgrade
KRYS Krystal Biotech	4.1259 of 5 stars	$335.73 +1.0%	$365.40 +8.8%	+130.3%	$9.83B	$440.48M	42.07	210	Positive News Analyst Downgrade
NUVL Nuvalent	2.121 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. PRAX, PTGX, KRYS, NUVL, and KYMR

How does SELLAS Life Sciences Group compare to Praxis Precision Medicines?

Summary

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Summary

How does SELLAS Life Sciences Group compare to Nuvalent?

Summary

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. PRAX, PTGX, KRYS, NUVL, and KYMR

How does SELLAS Life Sciences Group compare to Praxis Precision Medicines?

Do analysts prefer SLS or PRAX?

Is SLS or PRAX more profitable?

Does the media refer more to SLS or PRAX?

Do institutionals and insiders have more ownership in SLS or PRAX?

Which has stronger earnings & valuation, SLS or PRAX?

Which has more risk & volatility, SLS or PRAX?

Summary

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Is SLS or PTGX more profitable?

Does the media favor SLS or PTGX?

Do analysts recommend SLS or PTGX?

Which has more risk & volatility, SLS or PTGX?

Which has better valuation & earnings, SLS or PTGX?

Do insiders & institutionals believe in SLS or PTGX?

Summary

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Which has preferable earnings & valuation, SLS or KRYS?

Do analysts prefer SLS or KRYS?

Do institutionals and insiders believe in SLS or KRYS?

Which has more volatility and risk, SLS or KRYS?

Does the media refer more to SLS or KRYS?

Is SLS or KRYS more profitable?

Summary

How does SELLAS Life Sciences Group compare to Nuvalent?

Do insiders and institutionals have more ownership in SLS or NUVL?

Do analysts rate SLS or NUVL?

Which has higher earnings and valuation, SLS or NUVL?

Which has more risk & volatility, SLS or NUVL?

Does the media favor SLS or NUVL?

Is SLS or NUVL more profitable?

Summary

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Does the media refer more to SLS or KYMR?

Is SLS or KYMR more profitable?

Which has stronger earnings and valuation, SLS or KYMR?

Do insiders & institutionals have more ownership in SLS or KYMR?

Do analysts recommend SLS or KYMR?

Which has more volatility and risk, SLS or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools